STOCK TITAN

[Form 4/A] Tivic Health Systems, Inc. Amended Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4/A
Rhea-AI Filing Summary

Tivic Health Systems insider amendment: This Form 4/A reports a corrected disclosure for an equity award to Lisa G. Wolf, Chief Financial Officer and director. The amendment fixes an administrative error in the original filing and confirms an employee stock option granted on 08/06/2025 for 80,000 shares of common stock with an exercise price of $3.32. The option vests 25% on the first anniversary of the grant and the remaining 75% in 12 equal quarterly installments, fully vesting on the fourth anniversary; the option expires 08/05/2035. The filing is signed by an attorney-in-fact and does not disclose any cash proceeds or sales.

Emendamento interno di Tivic Health Systems: Questo Form 4/A segnala una divulgazione correttiva relativa a una sovvenzione azionaria a Lisa G. Wolf, Chief Financial Officer e membro del consiglio. L'emendamento corregge un errore amministrativo nella dichiarazione originale e conferma un opzione azionaria per dipendenti concessa il 08/06/2025 per 80.000 azioni ordinarie con un prezzo di esercizio di $3.32. L'opzione matura per il 25% al primo anniversario della concessione e il restante 75% in 12 rate trimestrali uguali, maturando completamente al quarto anniversario; l'opzione scade il 08/05/2035. La dichiarazione è firmata da un procuratore e non segnala alcun ricavo in contanti o vendite.

Enmienda interna de Tivic Health Systems: Este Form 4/A informa una divulgación corregida sobre una concesión de acciones a Lisa G. Wolf, directora financiera y miembro del consejo. La enmienda corrige un error administrativo en la presentación original y confirma una opción sobre acciones para empleados otorgada el 06/08/2025 por 80.000 acciones ordinarias con un precio de ejercicio de $3.32. La opción vence en un 25% al primer aniversario de la concesión y el 75% restante en 12 cuotas trimestrales iguales, consolidándose totalmente en el cuarto aniversario; la opción expira el 05/08/2035. La presentación está firmada por un apoderado y no divulga ingresos en efectivo ni ventas.

Tivic Health Systems 내부 수정서: 이 Form 4/A는 최고재무책임자 겸 이사인 Lisa G. Wolf에 대한 주식보상 공시에 대한 정정 내용을 보고합니다. 본 수정서는 원래 제출서의 행정적 오류를 수정하고 2025-08-06일에 부여된 종업원 스톡옵션을 확인합니다. 해당 옵션은 보통주 80,000주에 대한 것으로 행사가격은 $3.32입니다. 옵션은 부여일로부터 1주년 시점에 25%가 가속되고 나머지 75%는 12회의 동일한 분기별 할부로 가속되어 4주년에는 완전 가속되며, 옵션 만료일은 2035-08-05입니다. 제출서는 대리인이 서명했으며 현금 수익이나 매각 내역은 공개하지 않습니다.

Avenant interne de Tivic Health Systems : Ce Form 4/A signale une divulgation corrigée concernant une attribution d'actions à Lisa G. Wolf, directrice financière et administratrice. L'avenant corrige une erreur administrative dans le dépôt initial et confirme une option d'achat d'actions pour employé accordée le 06/08/2025 pour 80 000 actions ordinaires avec un prix d'exercice de 3,32 $. L'option acquiert 25 % des droits au premier anniversaire de l'attribution et les 75 % restants en 12 versements trimestriels égaux, atteignant la pleine acquisition au quatrième anniversaire ; l'option expire le 05/08/2035. Le dépôt est signé par un mandataire et ne révèle aucun produit en espèces ni vente.

Tivic Health Systems Insider-Nachtrag: Dieses Form 4/A meldet eine korrigierte Offenlegung für eine Aktienzuteilung an Lisa G. Wolf, Chief Financial Officer und Direktorin. Der Nachtrag behebt einen administrativen Fehler in der ursprünglichen Einreichung und bestätigt eine Mitarbeiter-Aktienoption, die am 06.08.2025 für 80.000 Stammaktien mit einem Ausübungspreis von $3.32 gewährt wurde. Die Option vestet zu 25% am ersten Jahrestag der Gewährung und die verbleibenden 75% in 12 gleichen vierteljährlichen Raten, mit vollständigem Vesting am vierten Jahrestag; die Option verfällt am 05.08.2035. Die Einreichung ist von einem Bevollmächtigten unterschrieben und gibt keine Bargelderlöse oder Verkäufe an.

Positive
  • Amendment corrects an administrative error and clarifies the stock option vesting schedule
  • Discloses full terms of the option: 80,000 shares, $3.32 exercise price, grant date 08/06/2025, expiration 08/05/2035
  • Vesting structure aligns with standard retention practices (25% after one year, remainder over 12 quarterly installments)
Negative
  • None.

Insights

TL;DR Routine correction clarifies vesting schedule for CFO option grant; no sales or dispositions reported.

This amendment corrects an administrative error in the original Form 4 and restates the material terms of an employee stock option granted to the reporting person. The key items disclosed are the grant date (08/06/2025), number of options (80,000), exercise price ($3.32), vesting schedule (25% at one year, remainder over 12 quarterly installments), and expiration date (08/05/2035). There are no reported dispositions or cash transactions in this filing. For investors, this is a governance and compensation disclosure rather than an economic event affecting company cash flows.

TL;DR Amendment improves disclosure accuracy for executive compensation; standard long-term vesting preserves retention incentives.

The Form 4/A demonstrates corrective action to ensure accurate public disclosure of equity-based compensation for the CFO. The four-year vesting schedule with an initial 25% cliff followed by quarterly vesting is a common retention structure. The document contains no indication of accelerated vesting, accelerated exercise, or related-party transfers. The amendment enhances transparency but does not introduce new material information beyond confirming the previously reported grant terms.

Emendamento interno di Tivic Health Systems: Questo Form 4/A segnala una divulgazione correttiva relativa a una sovvenzione azionaria a Lisa G. Wolf, Chief Financial Officer e membro del consiglio. L'emendamento corregge un errore amministrativo nella dichiarazione originale e conferma un opzione azionaria per dipendenti concessa il 08/06/2025 per 80.000 azioni ordinarie con un prezzo di esercizio di $3.32. L'opzione matura per il 25% al primo anniversario della concessione e il restante 75% in 12 rate trimestrali uguali, maturando completamente al quarto anniversario; l'opzione scade il 08/05/2035. La dichiarazione è firmata da un procuratore e non segnala alcun ricavo in contanti o vendite.

Enmienda interna de Tivic Health Systems: Este Form 4/A informa una divulgación corregida sobre una concesión de acciones a Lisa G. Wolf, directora financiera y miembro del consejo. La enmienda corrige un error administrativo en la presentación original y confirma una opción sobre acciones para empleados otorgada el 06/08/2025 por 80.000 acciones ordinarias con un precio de ejercicio de $3.32. La opción vence en un 25% al primer aniversario de la concesión y el 75% restante en 12 cuotas trimestrales iguales, consolidándose totalmente en el cuarto aniversario; la opción expira el 05/08/2035. La presentación está firmada por un apoderado y no divulga ingresos en efectivo ni ventas.

Tivic Health Systems 내부 수정서: 이 Form 4/A는 최고재무책임자 겸 이사인 Lisa G. Wolf에 대한 주식보상 공시에 대한 정정 내용을 보고합니다. 본 수정서는 원래 제출서의 행정적 오류를 수정하고 2025-08-06일에 부여된 종업원 스톡옵션을 확인합니다. 해당 옵션은 보통주 80,000주에 대한 것으로 행사가격은 $3.32입니다. 옵션은 부여일로부터 1주년 시점에 25%가 가속되고 나머지 75%는 12회의 동일한 분기별 할부로 가속되어 4주년에는 완전 가속되며, 옵션 만료일은 2035-08-05입니다. 제출서는 대리인이 서명했으며 현금 수익이나 매각 내역은 공개하지 않습니다.

Avenant interne de Tivic Health Systems : Ce Form 4/A signale une divulgation corrigée concernant une attribution d'actions à Lisa G. Wolf, directrice financière et administratrice. L'avenant corrige une erreur administrative dans le dépôt initial et confirme une option d'achat d'actions pour employé accordée le 06/08/2025 pour 80 000 actions ordinaires avec un prix d'exercice de 3,32 $. L'option acquiert 25 % des droits au premier anniversaire de l'attribution et les 75 % restants en 12 versements trimestriels égaux, atteignant la pleine acquisition au quatrième anniversaire ; l'option expire le 05/08/2035. Le dépôt est signé par un mandataire et ne révèle aucun produit en espèces ni vente.

Tivic Health Systems Insider-Nachtrag: Dieses Form 4/A meldet eine korrigierte Offenlegung für eine Aktienzuteilung an Lisa G. Wolf, Chief Financial Officer und Direktorin. Der Nachtrag behebt einen administrativen Fehler in der ursprünglichen Einreichung und bestätigt eine Mitarbeiter-Aktienoption, die am 06.08.2025 für 80.000 Stammaktien mit einem Ausübungspreis von $3.32 gewährt wurde. Die Option vestet zu 25% am ersten Jahrestag der Gewährung und die verbleibenden 75% in 12 gleichen vierteljährlichen Raten, mit vollständigem Vesting am vierten Jahrestag; die Option verfällt am 05.08.2035. Die Einreichung ist von einem Bevollmächtigten unterschrieben und gibt keine Bargelderlöse oder Verkäufe an.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wolf Lisa G

(Last) (First) (Middle)
47685 LAKEVIEW BLVD.

(Street)
FREMONT CA 94538

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tivic Health Systems, Inc. [ TIVC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
08/08/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Purchase) $3.32 08/06/2025 A 80,000 (1) 08/05/2035 Common Stock 80,000 $0.00 80,000 D
Explanation of Responses:
1. This Amendment No. 1 ("Form 4/A") to the Form 4 filed by the reporting person on August 8, 2025 (the "Original Form 4") is being filed to correct an administrative error, resulting in the incorrect vesting schedule for the stock option being included in the Original Form 4. As reflected in this Form 4/A, the stock option vests as follows: (i) 25% upon the first anniversary of the grant date, and (ii) the remaining 75% in a series of twelve (12) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the first anniversary of the grant date, such that 100% of the stock option will be vested upon the fourth anniversary of the grant date.
/s/ Jennifer Ernst, attorney-in-fact 08/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What change does the Form 4/A for TIVC report?

The Form 4/A corrects an administrative error in the original filing and clarifies the vesting schedule for an employee stock option granted to Lisa G. Wolf.

How many options were granted to the reporting person in this filing?

The filing reports an employee stock option for 80,000 shares of common stock.

What is the exercise price and expiration date of the option?

The option has an exercise price of $3.32 and an expiration date of 08/05/2035.

What is the vesting schedule disclosed in the amendment?

The option vests 25% on the first anniversary of the grant and the remaining 75% in 12 equal quarterly installments, fully vesting on the fourth anniversary.

Does the Form 4/A report any sales or cash proceeds?

No. The filing reports an option grant and does not disclose any dispositions, sales, or cash proceeds.
Tivic Health Systems Inc

NASDAQ:TIVC

TIVC Rankings

TIVC Latest News

TIVC Latest SEC Filings

TIVC Stock Data

3.48M
970.48k
10.39%
4.15%
3.68%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
FREMONT